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Abstract 
Little is known about the decisive molecular factors that regulate lesion remyelination 
in Multiple Sclerosis. To identify such factors, we performed a differential gene 
expression analysis of normal appearing white matter (NAWM), active, remyelinating, 
and inactive demyelinated lesions. As expected, many genes involved in 
inflammatory processes were detected to be differentially regulated between these 
tissue types. Among them, we found an increased expression of members of the 
STAT6 pathway such as STAT6, IL4 and IL4R in active, remyelinated and inactive 
demyelinated lesions. This suggests that a protective, anti-inflammatory reaction, as 
already reported to be present in MS NAWM, is further enhanced in lesion tissues. 
Focusing on genes influencing oligodendrogliogenesis, we found a decreased 
expression of NKX2-2 in active, remyelinated and inactive demyelinated lesions, 
whereas SOX10 was downregulated in inactive demyelinated lesions, when 
compared to NAWM. Simultaneously, CXCL12 (SDF1) expression was strongly 
increased in active, remyelinated and inactive demyelinated lesions, but increased 
expression of the IGF1 and IGF2 genes was found in inactive demyelinated lesions. 
This demonstrates that, in principle, expression of genes promoting 
oligodendrogliogenesis occurs in MS lesion tissue - even in inactive demyelinated 
lesions. In contrast, oligodendrogenesis inhibiting genes such as JAG1 were also 
expressed at higher levels in inactive demyelinated lesions. Both, 
oligodendrogliogenesis promoting as well as inhibiting genes are expressed in all 
lesion tissues. However, no clear promoting or inhibiting expression pattern could be 
detected in any of the different types of lesioned tissues. This might reflect the 
heterogeneity of lesion development in MS patients, both in terms of mechanisms 
and temporal differences. 
Keywords: Multiple Sclerosis, Gene expression analysis, Molecular pathology, 
Oligodendrogliogenesis, STAT6 pathway, Multiple Sclerosis lesions 
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Introduction 
 
Multiple Sclerosis (MS) is a chronic inflammatory, demyelinating disease of the 
central nervous system (CNS) with a large degree of heterogeneity in clinical course 
and histopathology  (Compston and Coles, 2002). It is suggested that MS is an 
autoimmune disorder directed against CNS antigens, which leads to inflammation 
and demyelination (Hemmer et al., 2002; Noseworthy et al., 2000). However, other 
findings suggest that the primary cause for inflammation in MS could be primary 
oligodendrocyte degeneration (Barnett and Prineas, 2004; Trapp, 2004). One major 
characteristic of MS is the formation of the so-called plaques or lesions; areas of 
demyelination in the white matter with variable levels of axonal damage (Lassmann, 
1998) (Figure1). The mechanisms underlying early lesion development are still 
unclear, but are thought to involve altered BBB permeability and nodules of activated 
microglial (van der Valk and Amor, 2009) in the normal appearing tissue, in which 
sub-pathological changes have been shown to be present (Filippi et al., 1998; 
Graumann et al., 2003; Lindberg et al., 2004; Zeis et al., 2008). Some of these areas 
of microglial activation are suggested to transform into full, active demyelinating 
lesions characterized by massive infiltration of immune cells, primarily of the 
monocyte/macrophage lineage.  
 
There is evidence that remyelination in the MS brain can be extensive, although 
highly heterogeneous (Trapp, 2004), and may be initiated in rapid succession 
following demyelination (Prineas et al., 1989; Raine and Wu, 1993). Depending on 
whether the process of repair and remyelination prevails over demyelination or not, 
active lesions develop into inactive demyelinated lesions, partially remyelinated or 
fully remyelinated lesions. To remyelinate, oligodendrocyte progenitor cells (OPCs) 
are recruited to repopulate the area of demyelination, differentiate into 
oligodendrocytes and remyelinate the demyelinated axons (Franklin, 2002). During 
these steps, OPCs have to migrate, proliferate and differentiate; processes that have 
to be tightly controlled by numerous molecular events, including axonal electrical 
activity (Franklin, 2002; Franklin and Ffrench-Constant, 2008; Gautier et al., 2015). 
Failure of remyelination results in inactive demyelinated lesions, in which myelin has 
been removed, immune cells are largely absent and the remaining demyelinated 
axons are embedded in a glial scar (Compston et al., 2006). 
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Substantial progress has been made in understanding the molecular mechanisms of 
remyelination. However, the overall nature and timing of molecular signaling 
influencing remyelination in MS lesion development and resolution are still 
incompletely understood. To identify genes involved in lesion formation and 
resolution, we performed a differential gene expression analysis between the distinct 
histological tissue types from brain autopsies of MS cases: normal appearing white 
matter (NAWM), active lesions (AL), remyelinating lesions (RL) and inactive 
demyelinated lesions (IdL). We found several genes involved in inflammatory 
processes to be differentially regulated. We further aimed to identify genes known to 
be involved in oligodendrogliogenesis in order to identify potential key factors in 
oligodendrocyte repair/remyelination. In all tissues, we found altered expression of 
genes both promoting and inhibiting oligodendrogliogenesis. Our study shows that 
the molecular pattern of pathohistologically similar tissues can be quite variable, 
possibly reflecting the heterogeneity of lesion development and repair in MS brain 
tissue.  
 
Materials and Methods 
 
Tissue collection 
MS and control tissue samples were supplied by the UK Multiple Sclerosis Tissue 
Bank (UK Multicentre Research Ethics Committee, MREC/02/2/39), funded by the 
Multiple Sclerosis Society of Great Britain and Northern Ireland (registered charity 
207495). For this study, tissue samples representing different tissue types were 
isolated from a total of 7 progressive MS cases (4 SPMS, 3 PPMS; Table 1). The 
median disease duration was 21 years (range from 11 to 27). The median age at 
death was 40 years (range from 34 to 49). Altogether, 7 remyelinating lesions, 9 
NAWM regions, 9 active lesions and 5 inactive demyelinated lesions were dissected 
(see Table 1). All brains had been screened by a neuropathologist to confirm 
diagnosis of MS and to exclude other confounding pathologies. All tissues were 
screened for the presence of T-cells (CD3), activated microglia and macrophages 
(CD68), activated astrocytes (GFAP) and signs of demyelination and remyelination 
(MOG, PLP) (Figure 1). Regions of interest for RNA isolation were dissected 
manually from several 20m cryosections per block. In regular intervals, sections 
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were analysed by immunohistochemistry to confirm tissue characteristics and to 
exclude contamination of the dissected tissue sample with other tissue types. 
 
Tissue characterization and definition 
Immunostaining against MOG and HLA-DR, as well as Luxol fast blue (LFB) 
histology, were performed to characterize and differentiate the tissue types (Figure 
1), as suggested by Kuhlmann et al (Kuhlmann et al., 2017). NAWM tissue was 
characterized by a normal myelin (Figure 1A) and microglial staining at least 10mm 
from areas of visible demyelination (Figure 1A, B). Active lesions (AL) showed a loss 
of myelin (Figure 1C) and the presence of activated microglia/macrophages 
containing myelin debris (Figure 1D, E). Remyelinating tissue was characterized by 
pale or thinly myelinated fibres with MOG+ oligodendrocytes in areas of ongoing 
inflammation (Figure 1F, G and H) or characterized by areas of pale LFB+ myelin 
staining (Figure 1I, J) with some residual activated microglia/macrophages (Figure 
1K). Inactive demyelinated lesions (IdL) were completely demyelinated with a well 
demarcated border (Figure 1L) and very few macrophages (Figure 1M). 
 
Immunohistochemistry 
All tissue samples were analysed by immunohistochemistry. Cryostat sections 
(10m) used for tissue characterization using anti-HLA-DR, -MBP and -MOG 
antibodies were fixed for 10min in 10% formalin. For inactivation of endogenous 
peroxidase, all sections were treated with 0.3% hydrogen peroxide and blocked with 
blocking buffer (1% normal donkey serum, 2% Fish skin gelatin, 0.15% Triton). After 
quenching, sections were incubated with primary antibodies overnight at 4°C. 
Secondary biotinylated antibodies were applied for 1 hour at room temperature 
followed by the ABC complex reagent (Vector Labs) for 1 hour. Color reaction was 
performed with 3-Amino-9-ethylcarbazole or diaminobenzidine (Erne et al., 2002). 
Counterstaining was performed in haematoxylin for 1 minute followed by rinsing the 
slide in running tap water. Antibodies used are shown in Table 2. 
 
Total RNA preparation 
Serial sections (20µm) were prepared, following tissue characterization and 
identification of regions of interest (above), for the isolation of total RNA. Tissue was 
isolated by micro-dissecting areas of NAWM, AL, aRL, cRL or Idl with reference to 
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the characterized sections from a minimum of 3 serial 20m sections. At regular 
intervals, sections were analysed by immunohistochemistry to confirm tissue 
characteristics and to exclude contamination of tissue sample with other tissue types. 
Samples were handled and cut in such a way that they never thawed and the 
cryostat, dissecting equipment and collection tubes were treated with RNaseZap 
(ThermoFisher Scientific) or certified free of RNase/ DNase contamination. Total 
RNA isolation was performed by homogenizing the tissue in guanidinium thiocyanate 
followed by a CsCl ultracentrifugation (Graumann et al., 2003). Freshly isolated RNA 
was tested for integrity using an Agilent 2100 Bioanalyser instrument (Agilent, Santa 
Clara, California, USA; all samples had an RNA Integrity Number of >7) and by 
Northern blot analysis for the expression of GFAP mRNA, as previously described 
(Graumann et al., 2003). 
 
Atlas™ cDNA Expression Array hybridization 
For this analysis, a custom made Clontech Atlas™ cDNA Expression Array was 
made which contains 1’185 selected cDNA sequences on a nylon membrane. Genes 
spotted on the nylon membrane were based on the data of earlier gene expression 
studies (Graumann et al., 2003 and Zeis et al., 2008) as well as on literature 
searches for genes involved in oligodendrogenesis (detailed list is found in 
Supporting information Table 1) resulting in an array focused on CNS and especially 
oligodendrogliogenesis relevant genes. Array hybridization was performed according 
to Graumann et al., (2003). Hybridization signals were detected with the 
phosphoimaging system (GE Healthcare Europe, Amersham, Molecular Dynamics, 
Glattbrugg, Switzerland). Differential gene expression analysis was made with 30 
total RNA samples of different origin from 7 patients (Table 1). From 1’185 genes 
present on the array, 1,099 genes were detectable at least in one tissue group 
(NAWM, AL, RL and IdL), whereas 86 were not detectable in any tissue groups.  
 
qRT-PCR 
Quantitative RT-PCR was performed in 384-well plates (VWR, Radnor, USA, Cat.No. 
82006-678) using the ABI ViiA Fast Real-Time PCR system (Applied Biosystems, 
Life technologies Ltd., Paisley, UK). Primer sequences were designed from unique 
sites over exon–intron junctions to prevent amplification of genomic DNA. Real-time 
RT-PCR was performed according to the manufacturer's protocol using the KAPA 
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SYBR Fast Universal 2x qPCR Master mix (KAPA Biosystems, Woburn, USA). RNA 
amounts were calculated with relative standard curves for all mRNAs of interest. 
qRT-PCR was normalized  with the H1FX, RPL3 and RPS6KA3 housekeeping 
genes. 
 
Gene expression analysis, statistics and pathway analysis 
Quantification of differential hybridization signal intensities was achieved with the 
AtlasImage™ 2.0 software program. A log2 transformation was then applied to the 
raw intensity values of each array. Normalization was completed using the quantile 
normalization method. Expression data were analysed using R and the software 
package limma (Phipson et al., 2016; R developmental Core Team, 2008; Ritchie et 
al., 2015). Statistical analysis was performed using the linear model with tissue type, 
patient and batch as factors. Genes with a p-value below 0.05 (p<0.05) were 
considered significantly changed between groups. Fold changes above 1.5 are 
considered to be higher expressed, whereas fold changes below -1.5 are considered 
to be lower expressed in the different tissue types. Data were further analysed with 
IPA (Ingenuity® Systems, www.ingenuity.com). All genes with a fold change 
higher/lower than +/-1.5 were used for the ingenuity pathway analysis. Analysis was 
performed comparing all different tissue types. 
Results 
Similarities and differences in gene expression between the different MS tissue 
types 
As a first step, we performed LFB staining as well as a detailed immunohistochemical 
analysis of all MS brain tissues to identify the different tissue types (NAWM, AL, RL 
and IdL; Figure 1), a prerequisite for our differential gene expression analysis. All 
gene expression data were compared between the different tissue types (Figure 2, 
Supporting information Table 1), representative for specific stages in lesion 
development (Figure 1).  
 
To identify genes which might be involved in the initiation further development of 
lesions, we first compared the gene expression patterns between AL and NAWM. 
From the 1,185 genes present on the array, 47 were significantly differentially 
expressed (p < 0.05, |FC| > 1.5) between AL and NAWM (Fig. 2A). Among them, 17 
had increased and 30 decreased expression in AL tissue.  
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A comparison between RL tissue, which is in the process or at the end of 
remyelination, and NAWM would be expected to reveal genes involved in 
remyelination or genes involved in the maintenance of oligodendrocytes. This 
comparison between RL and NAWM revealed 57 genes to be significantly 
differentially expressed. Expression of 28 genes was increased, whereas the 
expression of 29 genes was reduced in RL tissue (Fig. 2B).  
 
Comparing gene expression of NAWM with IdL would be expected to reveal 
significant reduction in expression of oligodendrocyte specific genes due to the 
oligodendrocyte loss in IdL. Furthermore, this comparison serves as a positive 
experimental control, as myelin gene expression was reduced as anticipated in IdL 
lesions compared to NAWM (Fig. 2C). Finally, genes involved in the initiation or 
regulation of oligodendrogliogenesis might either be up- or downregulated in IdL. 
Reflecting the cellular changes, the most significantly differentially expressed genes 
were found between IdL and NAWM, where 50 genes were increased and 110 genes 
were decreased in IdL (Fig. 2C).  
 
The comparison of AL and RL potentially reveals genes that are necessary for the 
initiation of remyelination. However, the fewest significantly differentially expressed 
genes were found between AL and RL. Only 3 genes were significantly increased 
and 6 genes significantly decreased in AL tissue in comparison to RL (Fig. 2D). 
Differences in gene expression between AL and IdL might be expected to reveal 
genes inhibiting remyelination and/or promoting astrogliogenesis/scar formation. 
Comparison between AL and IdL revealed 74 significantly differentially expressed 
genes, of which 55 were increased and 19 decreased, in AL tissue (Fig. 2E). 
Comparing RL and IdL gene expression should reveal genes involved in 
remyelination or genes inhibiting remyelination. 33 genes were found to be 
significantly differentially expressed between RL and IdL tissues. Expression of 23 
genes was increased and 10 decreased in RL tissue (Fig. 2F).  
 
A summary of the top 30 most changed genes between all tissue types and possibly 
the most relevant in lesion development and resolution is shown in Table 3. A 
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detailed list of all differentially expressed genes can be found in Supporting 
information Table 1. 
 
Comparison of remyelinating and chronic silent lesions did not reveal a clear 
promotion of oligodendrogliogenesis. 
In RL tissue, remyelination has either already taken place or is ongoing. In contrast, 
in IdL it is assumed that remyelination has failed. Therefore, it might be expected that 
this comparison might reveal genes important for remyelination or inhibition thereof. 
Analysis of differential gene expression of RL vs IdL, however, did not reveal a clear 
result. As expected, we detected a reduced expression of several genes known to be 
expressed in oligodendrocytes in IdL, such as e.g. GJB1, MAG, SOX10 or MAL 
(Table 4). We then searched for genes influencing oligodendrogliogenesis in RL and 
found JAG2 expression, known to inhibit oligodendrogliogenesis, to be reduced in RL 
vs IdL (p=0.02, Table 4). We also found CNTN2 (p=0.01) and SOX10 (0.01), both 
known to promote oligodendrogliogenesis (Zoupi et al., 2018), to be more highly 
expressed in RL. In contrast, expression of IGF2 (p=0.01) and MARCKS (p=0.05), 
both thought to positively influence oligodendrogliogenesis, were reduced in RL than 
in IdL (Table 4). Altogether, no clear pattern of genes promoting or inhibiting 
oligodendrogliogenesis was detected between RL and IdL tissue.  
 
Cluster analysis reveals heterogeneity between the different tissue types 
To analyze and characterize the differential gene expression between NAWM, AL, 
RL and IdL in more detail, a cluster analysis was performed (Figure 3). Basically, 
three clusters were detected. Cluster I mainly included NAWM (Figure 3). Six out of 9 
NAWM samples were found in cluster I whereas one was found in cluster II and two 
in cluster III. Cluster II included most IdL tissue samples of which 4 of 5 were found in 
this cluster (Figure 3). One IdL sample was found in cluster III. Both AL and RL tissue 
samples were dispersed throughout all three clusters and did not separate in two 
separate clusters, despite some similarities in immunohistological appearance. No 
clustering was detected when the confounding factors, batch and patient, were 
analysed.  
 
Genes involved in oligodendrogliogenesis are differentially expressed between 
NAWM, AL, RL and IdL 
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For successful remyelination to occur, OPCs have to become activated, recruited to 
the lesion area and differentiate into remyelinating oligodendrocytes (Franklin and 
Ffrench-Constant, 2008). By analyzing the differential gene expression pattern, we 
found altered expression of many genes influencing oligodendrogliogenesis (Table 4, 
Figure 5) in a positive and negative way in all the different tissue types. 
 
We found the expression of IGF1, reported to influence oligodendrogliogenesis (Beck 
et al., 1995; Carson et al., 1993; Huang and Dreyfus, 2016; McMorris et al., 1986), to 
be significantly elevated in IdL in comparison to NAWM (p=0.019, Figure 4A). In 
comparison to NAWM, IGF1 expression was increased in some AL and RL, but this 
was not a consistent result. IGF1 and IGF2 expression were significantly increased in 
IdL in comparison to NAWM (p=0.015). IGF2 expression was significantly reduced in 
RL in comparison to IdL (p=0.008, Figure 4B). Fibroblast growth factors, such as 
FGF2 and FGF9, have been reported to be involved in oligodendrocyte maturation 
(Fortin et al., 2005; Furusho et al., 2012; Lindner et al., 2015; McKinnon et al., 1990). 
However, we found no significant difference in FGF expression between the 
analysed tissue types. Some cases showed a strong increase in FGF2 and FGF9, 
whereas in others FGFs were down regulated. FGFR4 expression showed a trend to 
be increased in RL vs. NAWM (p=0.076, Figure 4C), and FGFR1-3 expression did 
not significantly change between NAWM, AL, RL and IdL. 
 
Oligodendrocyte differentiation has been shown to be influenced by the notch 
signaling pathway (Popko, 2003), which can either inhibit (Genoud et al., 2002; Wang 
et al., 1998) or promote oligodendrocyte maturation (Aparicio et al., 2013; 
Grandbarbe et al., 2003; Hu et al., 2003), depending on the stimulus. Here, we found 
a trend towards a higher expression of JAG1 in IdL in comparison to NAWM 
(p=0.076). In contrast, activation by F3/contactin (CNTN1) promotes OPC 
differentiation / maturation (Aparicio et al., 2013). However, no significant difference 
in CNTN1 or CNTN2 expression was detected in MS tissues. NOTCH1 expression 
itself showed a trend towards being reduced in RL (p=0.06) in comparison to NAWM.  
 
CXCL12/CXCR4 signaling has been demonstrated to be involved in 
oligodendrogliogenesis (Dziembowska et al., 2005; Zilkha-Falb et al., 2016). In 
comparison to NAWM, CXCL12 expression was significantly higher in AL (p=0.019), 
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RL (p=0.006) as well as IdL (p=0.002) (Figure 4C). In contrast, CXCR4 expression 
was not significantly changed between the different tissue types. Oligodendrocyte 
differentiation and maturation is further regulated by NKX2-2 (Qi et al., 2001). In the 
different tissue types, NKX2-2 expression was significantly lower in AL (p=0.008) and 
IdL (p=0.003), but not in RL (Figure 4D). The terminal differentiation of 
oligodendrocytes is dependent on the transcription factor Sox10 (Stolt et al., 2002). 
The expression of SOX10 was significantly reduced in IdL in comparison to AL 
(p=0.032), RL (p=0.007) and NAWM (p=0.005, Figure 4E). Finally, SEMA3B has 
been shown to inhibit oligodendrocyte migration (Cohen et al., 2003). In our gene 
expression analysis, SEMA3B expression was significantly increased in NAWM in 
comparison to AL (p=0.019), RL (p=0.041) and IdL (p=0.006, Figure 4F).  
 
Genes involved in the STAT6 signaling pathway are differentially expressed in 
lesion tissue 
We have previously reported that members of the STAT6 signaling pathway are 
upregulated in NAWM in comparison to control WM (Zeis et al., 2008). Here we show 
that the expression of members of the STAT6 signaling pathway, such as STAT6 
itself, IL4 and IL4R, is increased in AL, RL and IdL tissue (Table 5, Figure 4G, H, I). 
STAT6 expression is significantly higher in AL, RL and IdL lesions (Figure 4G). IL4 
expression showed a strong tendency to be increased in RL in comparison to NAWM 
(p=0.051) and in AL and IdL (Figure 4H). Finally, IL4R expression was significantly 
higher in RL and IdL in comparison to NAWM. In AL, IL4R expression showed a 
trend towards being increased but not in all cases (Figure 4I). Expression of JAK1 
and JAK3 did not show any significant expression changes between NAWM, AL, RL 
and IdL. 
 
Expression of myelin genes decreases from NAWM to IdL tissue 
The expression of myelin genes MAG, MAL (Figure 4J), MOBP, MOG (Figure 4K), 
and PLP1 (Figure 4L), with the exception of MBP, was not significantly changed in 
AL or RL in comparison to NAWM. In contrast, myelin gene expression was strongly 
reduced in IdL in comparison to NAWM (Table 4). However, MBP gene expression 
was significantly increased in RL in comparison to NAWM (Table 4). 
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Pathway analysis shows a strong immune activation in all tissues in 
comparison to NAWM 
To investigate possible pathways and/or networks involved in lesion formation or 
resolution, we performed an Ingenuity pathway core analysis between all different 
tissue types (Table 6). Compared to NAWM, an increased proliferation of immune 
cells was predicted in all lesion types (activation z-score; AL: 1.806, RL: 2.296, IdL: 
2.434). Moreover, an increased activation of many different immune system functions 
was predicted in AL, RL and IdL in comparison to NAWM (Table 6). Interestingly, a 
significant activation of development of neurons pathways was predicted in AL tissue 
in comparison to NAWM (p= 2.08E-12, activation z-score=2.672). In addition, cell 
viability of neuroglia was also predicted to be increased in AL (p=3.89E-13, activation 
z-score=2.260). In the comparison of RL vs NAWM, an increase of myelination was 
predicted (p=3.28E-15, activation z-score=2.170). 
 
Comparison between AL and RL revealed a predicted decrease in several functions 
associated with immune system function such as, cell movement of phagocytes 
(p=6.26E-27, activation z-score=-3.419) and leukocyte migration (p=1.07E-31, 
activation z-score=-2.768) in the AL tissue. Finally, analysis of the differential gene 
expression between RL and IdL revealed a predicted increase of lymphocyte 
stimulation (p=1.18E-09, activation z-score=2.211) and genes involved in systemic 
autoimmune disease (p=7.03E-19, activation z-score=2.672). 
 
qRT-PCR verification 
To verify the results of the differential gene expression study, we performed a qRT-
PCR analysis on a different set of tissues from 9 different MS patients. In total the 
expression of IGF2, CXCL12, STAT6, NPY, MAG as well as MAL was analysed on 
22 NAWM, 14 AL, 8 RL and 9 IdL tissue samples (Table 7). Overall, qRT-PCR 
confirmed the results from the ATLAS cDNA gene expression array. In the 
comparison of RL vs NAWM, NPY, STAT6 and MAG showed a similar increase or 
decrease in expression in qRT-PCR as in the array study, but without significance 
(NPY; p=0.105, STAT6; p=0.300, MAG; p=0.149).    
 
Discussion 
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We have previously shown that there is a balance between proinflammatory genes, 
expressed mainly by microglia, and anti-inflammatory and neuroprotective genes, 
expressed predominantly by oligodendrocytes in the MS NAWM in comparison to 
control (Graumann et al., 2003; Zeis et al., 2008; Zeis et al., 2009). Therefore, it 
might be expected that a shift in the balance of these opposing processes might lead 
to the formation of lesions. To investigate this further, we analysed the gene 
expression of normal appearing white matter (NAWM), active, remyelinating and 
inactive demyelinating lesions with a focus on genes known to be involved in 
oligodendrocyte development and regeneration. By comparing the gene expression 
of the different tissue types, representative for lesion developmental stages, we 
speculated that depending on the comparison made, genes involved in various 
processes influencing lesion growth, repair or inactivation might be detected. We 
expected that genes involved in lesion growth and/or inflammatory processes might 
be detected in NAWM vs AL, whereas genes playing a role in lesion clearance/repair 
would be detected in the AL vs RL comparison. Comparing RL vs IdL might have 
been expected to reveal genes that play a role in either blocking or 
initiating/promoting remyelination. Our results show that our hypothesis was partially 
validated (Table 6). However, heterogeneity of gene expression in individual 
categories and, in retrospect the use of too broad a lesion staging process, made it 
challenging to detect clear differences between the data sets. 
 
The expression of many genes varied strongly across the different types of white 
matter tissue seen in the MS brain (NAWM, AL, RL, IdL). For example, the 
expression of the IGF1 gene varied by more than 128 fold between the different IdL 
tissue samples (Figure 4A), even though these tissue samples were similar at the 
immunohistochemical level. This heterogeneity could result from the different stages 
of lesion development and resolution in the samples, which would lead to changes in 
cell populations, or different pathogenetic mechanisms. Such variability in the 
expression of genes influencing oligodendrocyte development might be one of the 
causes for heterogeneous lesion outcome in MS patients. Lesion specific signaling, 
originating from the interplay between the different cells present, might lead to the 
reported phenomenon that in a single patient both successful remyelination and 
remyelination failure is detected (Patrikios et al., 2006). 
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There are potentially many causes for remyelination failure; non-disease-related 
factors (age, sex, genetic background; (Franklin and Ffrench-Constant, 2008), 
insufficient OPC availability (Ludwin, 1980; Mason et al., 2004), insufficient OPC 
migration (Boyd et al., 2013), deficient OPC differentiation, proliferation or 
myelination (Franklin and Ffrench-Constant, 2008; Wolswijk, 1998) or compromised 
axons unable to support their remyelination (Chang et al., 2002). Our results show 
that even in inactive demyelinated lesions, factors are present that could initiate 
and/or support remyelination (e.g. IGF1, IGF2 or CXCL12). We speculate that, 
although such factors are present, the simultaneous presence of factors opposing 
oligodendrocyte development (e.g. JAG1 (Wang et al., 1998)) might shift the balance 
in favor of demyelination. We also found an elevated expression of genes known to 
inhibit oligodendrogliogenesis in remyelinating lesion tissue (e.g. EDN1, TNC). We 
suggest that in this case, the expression of factors promoting remyelination exerted a 
stronger effect and neutralized the effects of genes inhibiting oligodendrocyte 
development, leading to successful remyelination. Furthermore, the timing of 
expression of developmental factors is crucial in oligodendrocyte development 
(Franklin, 2002; Franklin and Ffrench-Constant, 2008). Many factors can promote 
specific steps in oligodendrocyte development but have inhibiting properties at other 
stages. This is true for FGF2 or PDGF, which both promote OPC proliferation. Later 
however, PDGF slows down and FGF2 even inhibits differentiation (McKinnon et al., 
1993). Therefore, genes normally beneficial in oligodendrocyte development might 
be detrimental for remyelination if expressed at the wrong time point. Altogether, we 
did not detect a clear pro- or anti- oligodendrogliogenesis/remyelinating gene 
expression pattern in the different types of lesions (Figure 5). 
 
We previously reported an increased expression of STAT6 in the NAWM of MS 
patients in comparison to control patients (Zeis et al., 2008; Zeis et al., 2009). 
Furthermore, we demonstrated that in the NAWM, STAT6 is expressed mainly by 
oligodendrocytes and to a minor extent in astrocytes (Zeis et al., 2008). Interestingly, 
we found that STAT6, as well as two members of the STAT6 pathway, IL4 and IL4R, 
are higher expressed in AL, RL and IdL in comparison to NAWM. This suggests that 
a possible protective, anti-inflammatory reaction already activated in the NAWM, is 
intensified in zones of ongoing inflammation in MS, although other non-
immunological related functions cannot be ruled out (Zeis et al., 2016).   
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Pathway analysis of the differential gene expression between the different tissues is 
particularly difficult due to the highly variable cellular composition (Figure 1). This 
might result in a different RNA pool and, therefore, the resulting differential gene 
expression is predominantly defined by the change in cell type composition and 
changes in gene expression of resident cells might be masked. This is reflected by 
the results of the biological function analysis, which showed that the most enriched 
processes detected were related to the immune system (Table 6). However, in 
addition to that, we found a signature of an increased development of neurons, cell 
viability of CNS cells and axonogenesis in AL and myelination in RL tissue when 
compared with NAWM tissue. These signatures suggest that glial cells react to the 
inflammation with a protective response and/or infiltrating immune cells support the 
survival of resident cells by expressing genes supportive of cell viability. 
 
Understanding the signaling pathways leading to lesion remyelination in MS is key for 
devising therapies that enhance repair. Our study was designed to identify common 
factors that might distinguish the different tissue types (NAWM, AL, RL and IdL) and 
serve as therapeutic candidates to enhance remyelination. In summary, several 
different factors known to be involved in oligodendrocyte development were detected 
to be differentially regulated between the different tissue types (summarized in Figure 
5). However, no specific de- or remyelinating pattern was detected in either tissue 
type; rather a largely heterogeneous expression pattern of oligodendrogliogenesis 
influencing genes was detected between, but also within, the different lesion types. 
This indicates that at any one point in time in the MS brain, developing and repairing 
lesions can be present at many different stages, in keeping with a continuum of 
ongoing processes. A greater understanding of this heterogeneity is crucial if we are 
to understand the correct timing for delivery of agents that enhance remyelination. 
Therefore, a precise characterization of the temporal and spatial localization of pro-
repair factors is required. 
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Figure and Table Legends 
Figure 1: Tissue characterization 
All tissue blocks were stained with LFB (A, E, I, J), anti-HLA-DR (LN3, A, B, D, E, H, 
K, M) and anti-MOG (C, L) antibodies. Accordingly, tissue was characterized and 
subsequent sections selected for the micro-dissection of tissue for total RNA 
isolation. Normal appearing white matter tissue showed normal, non-pathological 
myelin (A) and microglia with a surveilant and ramified morphology (A, B). In contrast, 
active lesions showed a loss of myelin (C) as well as activated 
microglia/macrophages containing myelin lipids (D, E). Remyelinating tissue was 
either characterized as partially remyelinated lesions containing MOG+ 
oligodendrocytes and short myelin internodes in areas of ongoing inflammation (F, G 
and H) termed as active RL (aRL) or completely remyelinated (cRL) and 
characterized by the pale myelin staining (LFB) of the shadow plaque (I, J) 
accompanied by modest numbers of activated microglia/ macrophages (K). Inactive 
demyelinated tissue showed a complete demyelination (L) without significant active 
inflammation or myelin debris (M). Left panels: Schematic drawing of MS lesions 
show the simplified cellular situation in the specified tissue in order to visualize the 
cellularity defining the mRNA isolated. Oligodendrocytes and their myelin sheets 
(brown), astrocytes (green), microglia (yellow) as well as activated microglia / 
macrophage (grey) and other infiltrating immune cells of various types (blue) are 
shown. Asterisks = lesion tissue 
 
Figure 2: Differential gene expression between the different tissues 
Volcano plots of the differential gene expression in between the different tissues. All 
possible comparisons are shown. However, for better visibility, only a selection of 
gene names is shown. All genes with a p-value of less than 0.05 and a fold change of 
+/- 1.5 are marked by red or green color, respectively. Most significantly differential 
expressed genes were found between NAWM and IdL whereas the AL and RL 
tissues seemed to be the most similar.  
 
Figure 3: Cluster analysis 
Cluster analysis of the gene expression data from all samples reveals three main 
clusters. Cluster 1 contained most of the NAWM tissue (6 out of 9) whereas in cluster 
ACCEPTED MANUSCRIPT
AC
CE
PT
ED
 M
AN
US
CR
IP
T
 
2 most IdL tissues were found. AL and RL tissues were dispersed in all three 
clusters. Clusters were not formed by possible confounding factors such as patient or 
batch.  
 
Figure 4: Boxplots of selected genes 
Boxplots of differential gene expression between NAWM, AL, RL and IdL of selected 
genes are shown. A high variability in between samples of the same tissue type is 
visible for different genes, such as e.g. IGF1 (A), NKX2-2 (D, AL & IdL) and SEMA3B 
(F, AL). Whereas IGF1 (A) and IGF2 (B) expression shows no clear trend between 
the different tissue types, the expression of CXCL12 (C) is increased from NAWM to 
IdL lesion tissues. In contrast, the expression of NKX2-2 (D), SOX10 (E) and 
SEMA3B (F) are decreased from NAWM to IdL tissue. The expression of STAT6 (G) 
and IL4 (H) tend to be the highest in RL tissue, whereas the expression of IL4R (I) is 
highest in IdL. As expected, the expression of the myelin genes MAL (J), MOG (K) 
and PLP1 (M) is lowest in IdL tissues. 
 
Figure 5: Schematic drawing summarising the differential expression pattern of 
genes involved in oligodendrogliogenesis 
Summary scheme showing significantly differentially expressed genes involved in 
oligodendrogliogenesis between the different tissue types (Table 4). Genes are color 
coded according to their higher (green) or lower (red) expression in the tissue the 
color matching arrow points to.  
 
Table 1: Patient characterization 
Summary of clinical data and characterization of MS cases. Clinical and pathological 
information concerning the 7 progressive MS cases studied are shown. NAWM, 
normal appearing white matter, AL, active lesion, RL, remyelinating lesion, IdL, 
inactive demyelinated lesion.         
 
Table 2: Antibodies 
Antibodies used in this study. Table shows all antibodies, their origin and dilution 
used. Abbreviations: dk-a-rb, donkey anti rabbit; dk-a-m, donkey anti mouse; dk-a-gt, 
donkey anti goat.   
 
ACCEPTED MANUSCRIPT
AC
CE
PT
ED
 M
AN
US
CR
IP
T
 
Table 3: Top genes showing most significant changes between the different MS 
tissue types 
30 genes with most significant changes in gene expression between the different 
tissue types is shown. Genes with a p-value of less than 0.05 are marked by a grey 
background color and were further colored according to their fold change. Genes with 
a fold change higher than 1.5 were marked red. Genes with a fold change lower than 
-1.5 were marked green. 
 
Table 4: Differential expression of genes involved in oligodendrogenesis 
Differential gene expression of genes known to be involved in oligodendrogenesis. 
Differential gene expression was analysed between all four different tissue types (AL, 
RL, IdL and NAWM). Table shows relative fold changes in between the different 
tissue types of a selection of genes known to be involved in oligodendrogenesis. 
Genes with a p-value of less than 0.05 are shown in bold, and were colored 
according to their fold change. Genes with a fold change higher than 1.5 were 
marked red. Genes with a fold change lower than -1.5 were marked green.  
 
Table 5: Differential expression of STAT6 pathway genes 
Differential gene expression of genes of the STAT6 pathway. Relative fold changes 
are shown. Differential expression was analysed between AL, RL and IdL in 
comparison to NAWM. Statistically significant changes are marked in bold red. 
 
Table 6: Ingenuity pathway analysis 
Ingenuity pathway analysis of the differential gene expression between NAWM, AL, 
RL and IdL. Differential gene expression between NAWM, AL, RL and IdL was 
analysed to predict the increase/decrease of activation of particular functions in the 
different tissues. A selection of functions predicted to be activated/inhibited is shown.  
 
Table 7: qRT-PCR verification 
To verify the results from the ATLAS cDNA gene expression array we performed a 
quantitative RT-PCR analysis of selected genes. In a majority of comparisons the 
results from the ATLAS cDNA expression array matched with the qRT-PCR analysis. 
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Supplementary table 1: Differential gene expression analysis 
Table shows the fold change and p-value of all genes and comparisons investigating 
in this study. 
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Table 1                     
                      
Patient 
ID 
Age 
(yr) 
Sex 
MS 
Type 
Disease 
Duration 
(yrs) 
Postmortem 
Interval 
(hrs) 
Cause of Death NAWM AL RL IdL 
MS40 48 F PP 21 6 Bronchopneumonia 2 1 1 1 
MS79 49 F SP 23 7 Bronchopneumonia 1 1 1 1 
MS106 39 F PP 21 18 Bronchopneumonia 1 2 1 1 
MS122 44 M SP 16 16 Bronchopneumonia 1 3 2 1 
MS136 40 M SP 9 10 
Respiratory failure, 
sepsis 
2 1 1 1 
MS154 34 F SP 11 12 Pneumonia 1 1 - - 
MS176 37 M PP 27 12 
Intestinal 
obstruction 
1 - 1 - 
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Table 2: Antibodies       
        
Antibody Company Cat.Nr. Dilution 
        
Primary Antibodies 
        
anti-MOG (Clone Z12) kindly provided by Prof. 
R.Reynolds 
- 1:200 
anti-NEUN Millipore MAB377 1:500 
anti-GFAP Sigma-Aldrich G-3893 1:2000 
anti-CD68 Abcam ab845 1:500 
anti-LN3 Abcam ab49388 1:500 
anti-OLIG2 Millipore ab9610 1:500 
        
Secondary Antibodies 
        
dk-a-rb-Biotin Jackson ImmunoResearch 711-065-152 1:500 
dk-a-m-Biotin Jackson ImmunoResearch 715-065-151 1:500 
dk-a-gt-Biotin Jackson ImmunoResearch 705-065-147 1:500 
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Table 3 
       
 
 
AL RL IdL 
  
NAWM RL IdL NAWM IdL NAWM 
SYMBOL Gen name FC FC FC FC FC FC 
CXCL13 
chemokine (C-X-C motif) ligand 13 (B-cell 
chemoattractant) 
-1.39 -3.47 -5.95 2.50 -1.71 4.28 
PARP1 
ADP-ribosyltransferase (NAD+; poly (ADP-
ribose) polymerase) 
-1.01 -1.64 -1.78 1.62 -1.09 1.77 
PEA15 astrocytic phosphoprotein PEA-15 -1.03 1.48 1.48 -1.52 -1.00 -1.52 
SCD 
ACYL-COA DESATURASE (EC 1.14.99.5) 
(STEAROYL-COA DESATURASE) (FATTY 
ACID DESATURASE) (DELTA(9)-
DESATURASE). 
-1.81 1.40 2.10 -2.54 1.50 -3.80 
ACVRL1 activin A receptor type II-like 1 4.04 -1.10 -1.06 4.46 1.04 4.30 
ALCAM 
CD166 ANTIGEN PRECURSOR (ACTIVATED 
LEUKOCYTE-CELL ADHESION MOLECULE) 
(ALCAM). 
-1.51 1.13 2.78 -1.70 2.47 -4.20 
APP 
Alzheimer's disease amyloid A4 protein 
precursor; protease nexin-II (PN-II); APPI 
-1.33 1.58 2.23 -2.10 1.41 -2.95 
ATP5F1 
ATP SYNTHASE B CHAIN, 
MITOCHONDRIAL PRECURSOR 
-1.98 1.19 3.48 -2.35 2.93 -6.88 
CHRNA6 
cholinergic receptor, nicotinic, alpha 
polypeptide 6 
-2.30 -2.26 1.51 -1.02 3.41 -3.48 
COX5B 
CYTOCHROME C OXIDASE POLYPEPTIDE 
VB PRECURSOR (EC 1.9.3.1). 
-1.62 1.03 1.07 -1.67 1.04 -1.74 
CXCL12 
chemokine (C-X-C motif) ligand 12 
(stromal cell-derived factor 1) 
1.88 -1.20 -1.47 2.25 -1.22 2.76 
DAXX death-associated protein 6 1.38 1.26 -1.57 1.10 -1.98 2.17 
DYNLL1 
cytoplasmic dynein light chain 1 (HDLC1); 
protein inihibitor of neuronal nitric oxide 
synthase (PIN) 
-1.88 1.02 1.49 -1.91 1.46 -2.79 
EDIL3 INTEGRIN BINDING PROTEIN DEL-1. -1.54 1.04 2.89 -1.61 2.77 -4.45 
ELAVL3 
HU-ANTIGEN C (PARANEOPLASTIC 
CEREBELLAR DEGENERATION-
ASSOCIATED ANTIGEN). 
-1.18 1.13 2.06 -1.33 1.82 -2.43 
FSCN1 FASCIN (ACTIN BUNDLING PROTEIN). -1.14 1.52 2.00 -1.73 1.32 -2.28 
GJB1 
GAP JUNCTION BETA-1 PROTEIN 
(CONNEXIN 32) (CX32) (LIVER GAP 
JUNCTION PROTEIN) 
-1.33 -1.25 2.51 -1.06 3.14 -3.34 
GSTO1 
glutathione-S-transferase like; glutathione 
transferase omega 
-1.90 1.07 1.02 -2.03 -1.04 -1.95 
IL10RA interleukin 10 receptor, alpha 4.45 -1.21 -1.26 5.40 -1.04 5.60 
IL2RA interleukin 2 receptor, alpha -2.53 -1.02 1.00 -2.48 1.02 -2.53 
ITGA5 
integrin, alpha 5 (fibronectin receptor, 
alpha polypeptide) 
2.42 -1.14 -1.05 2.77 1.09 2.54 
ITSN1 intersectin 1 (SH3 domain protein) 1.58 -1.05 -1.31 1.67 -1.25 2.08 
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JAG2 jagged 2 1.07 1.04 -1.76 1.03 -1.82 1.88 
KCNJ2 
cardiac inward rectifying potassium 
channel 2  (KCNJ2); HIRK1; KIR2.1 
-1.72 -1.07 1.27 -1.61 1.36 -2.19 
KIF1A 
kinesin-like protein KIF1A; axonal 
transporter of synaptic vesicles 
-1.25 1.24 1.79 -1.56 1.44 -2.25 
MAG 
myelin-associated glycoprotein precursor 
(MAG) 
-1.46 -1.24 2.30 -1.18 2.86 -3.37 
MAL mal, T-cell differentiation protein -1.42 1.12 2.47 -1.59 2.20 -3.50 
MARCKS 
myristoylated alanine-rich C-kinase 
substrate (MARCKS); protein kinase C 
substrate 80-kDa protein light chain 
(PKCSL) 
1.28 -1.24 -2.11 1.58 -1.71 2.70 
MOG 
myelin-oligodendrocyte glycoprotein 
precursor (MOG) 
-1.44 1.01 1.23 -1.46 1.21 -1.76 
NPY neuropeptide Y -2.86 -1.07 1.05 -2.67 1.13 -3.00 
PIP4K2A 
phosphatidylinositol-4-phosphate 5-
kinase type III (PIP5K3); PTDINS(4)P-5-
kinase C isoform; diphosphoinositide 
kinase + phosphatidylinositol-4-
phosphate 5-kinase type II alpha 
(PIP5K2A); PTDINS(4)P-5-kinase B isoform 
-1.45 1.07 2.87 -1.56 2.68 -4.16 
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Table 
4: 
                
    
                 Relative fold changes 
Symbol 
  
Gene name 
AL RL IDL RL IDL RL 
  vs. NAWM vs. AL 
vs. 
IDL 
                  
    Growth factors             
                  
BMP2   bone morphogenetic protein 2 1.10 1.18 1.17 1.07 1.07 0.99 
FGF2   fibroblast growth factor 2 1.52 1.20 
-
1.08 
-
1.26 
-
1.64 
1.30 
FGF9   fibroblast growth factor 9 1.18 1.30 1.22 1.11 1.04 1.07 
IGF1   insulin-like growth factor 1 1.71 1.69 3.33 
-
1.01 
1.95 -1.97 
IGF2   insulin-like growth factor 2 1.54 
-
1.11 
2.90 
-
1.71 
1.88 -3.21 
JAG1   jagged 1 1.25 1.57 1.93 1.26 1.54 -1.23 
NTF3   neurotrophin 3 1.05 
-
1.30 
-
1.17 
-
1.37 
-
1.23 
-1.11 
PDGFA   
plateled-derived growth factor, alpha 
polypeptide 
-
1.11 
1.04 1.02 1.15 1.13 1.02 
                  
    Receptors             
                  
CNTFR   ciliary neurotrophic factor receptor 1.26 1.08 1.48 
-
1.16 
1.18 -1.37 
EGFR   epidermal growth factor receptor 1.29 1.31 
-
1.03 
1.01 
-
1.33 
1.34 
FGFR1   fibroblast growth factor receptor 1 1.16 1.43 1.38 1.24 1.20 1.04 
FGFR2   fibroblast growth factor receptor 2 
-
1.10 
1.27 1.12 1.40 1.23 1.14 
FGFR3   fibroblast growth factor receptor 3 
-
1.00 
1.32 1.60 1.32 1.60 -1.21 
FGFR4   fibroblast growth factor receptor 4 1.36 2.16 1.68 1.59 1.24 1.29 
LIFR   leukemia inhibitory factor receptor alpha 
-
1.72 
-
2.17 
-
1.65 
-
1.26 
1.04 -1.31 
NGFR   nerve growth factor receptor 
-
1.01 
2.04 2.33 2.06 2.36 -1.14 
NRP1   neuropilin 1 
-
1.04 
1.12 1.05 1.17 1.09 1.07 
NRP2   neuropilin 2 
-
1.07 
1.00 1.33 1.07 1.42 -1.33 
SEMA4
D 
  semaphorin 4D 1.08 1.27 1.08 1.17 
-
1.00 
1.17 
P2RX7  purinergic receptor P2X 7 
-
1.43 
-
1.98 
-
2.13 
-
1.38 
-
1.49 
1.08 
                  
    Transcription factors             
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NOTCH1   Notch1 
-
1.06 
-
1.38 
-
1.07 
-
1.30 
-
1.01 
-1.29 
NKX2-2   NK2 homeobox 2 
-
1.87 
-
1.49 
-
2.37 
1.25 
-
1.27 
1.59 
SOX2   SRY-box 2 1.08 1.40 1.47 1.30 1.36 -1.05 
SOX9   SRY-box 9 
-
1.03 
1.08 
-
1.10 
1.11 
-
1.07 
1.19 
SOX10   SRY-box 10 
-
1.32 
-
1.06 
-
2.70 
1.25 
-
2.04 
2.54 
                  
    Myelin genes             
                  
MAG   myelin-associated glycoprotein 
-
1.46 
-
1.18 
-
3.37 
1.24 
-
2.30 
2.86 
MAL   myelin and lymphocyte protein 
-
1.42 
-
1.59 
-
3.50 
-
1.12 
-
2.47 
2.20 
MBP   myelin basic protein 1.31 1.81 1.68 1.38 1.28 1.07 
MOBP   myelin-associated oligodendrocytic basic protein 
-
1.43 
-
1.71 
-
3.83 
-
1.20 
-
2.68 
2.24 
MOG   myelin oligodendrocyte glycoprotein 
-
1.44 
-
1.46 
-
1.76 
-
1.01 
-
1.23 
1.21 
PLP1   proteolipid protein 1 
-
1.52 
-
2.01 
-
5.96 
-
1.33 
-
3.93 
2.96 
SCD  stearoyl-CoA desaturase 
-
1.81 
-
2.54 
-
3.80 
-
1.40 
-
2.10 
1.50 
                  
    Cytokines             
                  
CXCL12   chemokine (C-X-C motif) ligand 12 1.88 2.25 2.76 1.20 1.47 -1.22 
IL6   interleukin 6 1.13 
-
1.05 
-
1.17 
-
1.18 
-
1.32 
1.12 
LIF   leukemia inhibitory factor 
-
1.61 
-
1.03 
-
1.22 
1.57 1.33 1.18 
                  
    Others             
                  
CSPG4   chondroitin sulfate proteoglycan 4 
-
1.11 
1.23 1.04 1.37 1.16 1.18 
TH   tyrosine hydroxylase 
-
1.11 
1.24 1.24 1.38 1.37 1.01 
PTPN11   
protein tyrosine phosphatase, non-receptor type 
11 
-
1.09 
-
1.46 
-
1.68 
-
1.34 
-
1.54 
1.15 
SEMA3B   semaphorin 3B 
-
1.69 
-
1.66 
-
2.16 
1.02 
-
1.28 
1.30 
RELN   reelin 1.01 
-
1.06 
-
1.19 
-
1.08 
-
1.21 
1.12 
NCAM1   neural cell adhesion molecule 1 
-
1.07 
-
1.54 
-
2.14 
-
1.44 
-
2.00 
1.39 
VTN   vitronectin 
-
1.21 
-
1.04 
-
1.47 
1.17 
-
1.22 
1.42 
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TNC   tenascin C 1.12 1.89 2.72 1.69 2.43 -1.44 
THRB   thyroid hormone receptor, beta 
-
1.48 
1.00 
-
1.10 
1.49 1.35 1.10 
MARCKS   
myristoylated alanine rich protein kinase C 
substrate 
1.28 
-
1.24 
-
2.11 
1.58 
-
1.71 
2.70 
GJB1  gap junction protein beta 1 
-
1.33 
-
1.25 
2.51 
-
1.06 
3.14 -3.34 
CNTN2  contactin 2 
-
1.20 
-
1.60 
1.51 1.34 2.24 -1.81 
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Table 5:         
              
    Gene NAWM AL RL IdL 
              
ST
A
T6
 P
at
h
w
ay
   
STAT6 1 1.99 2.7 3.1 
  
JAK1 1 1.1 0.83 1.12 
  
JAK3 1 0.67 0.76 0.88 
  
IL4 1 2.07 3.47 1.99 
  
IL4R 1 2.35 4.43 5.9 
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Table 6:       
        
Biological Function Annotation p-Value 
Predicted 
activation 
Activation 
z-score 
        
AL vs NAWM 
        
Development of neurons 2.08E-12 Increased 2.672 
Cell viability of central nervous system cells 6.95E-12 Increased 2.478 
Cell viability of neuroglia 3.89E-13 Increased 2.26 
Cell viability of myeloid cells 2.79E-13 Increased 2.138 
Stimulation of myeloid cells 1.31E-12 Increased 2.046 
Axonogenesis 2.33E-11 Increased 2.019 
        
RL vs NAWM       
        
Leukocyte migration 8.34E-37 Increased 2.651 
Development of neurons 3.23E-14 Increased 2.616 
Cell proliferation of T lymphocytes 4.49E-21 Increased 2.456 
Proliferation of immune cells 1.71E-22 Increased 2.296 
Proliferation of neuronal cells 4.42E-15 Increased 2.257 
Myelination 3.28E-15 Increased 2.17 
        
IdL vs NAWM       
        
Proliferation of lymphocytes 2.86E-34 Increased 2.728 
Proliferation of mononuclear leukocytes 4.67E-36 Increased 2.672 
Proliferation of immune cells 1.87E-37 Increased 2.434 
T cell migration 1.15E-19 Increased 2.14 
        
AL vs RL       
        
Cell movement of phagocytes 6.26E-27 Decreased -3.419 
Leukocyte migration 1.07E-31 Decreased -2.768 
Cellular infiltration by macrophages 2.38E-13 Decreased -2.692 
T cell response 3.40E-10 Decreased -2.33 
Proliferation of immune cells 3.10E-18 Decreased -2.294 
        
AL vs IdL       
        
Inflammation of organ 1.29E-39 Increased 2.748 
Viral Infection 9.85E-26 Increased 2.308 
Cell proliferation of tumor cell lines 1.96E-28 Increased 2.19 
        
RL vs IdL       
        
Systemic autoimmune syndrome 7.03E-19 Increased 2.672 
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Inflammation of organ 1.17E-23 Increased 2.522 
Stimulation of T lymphocytes 1.74E-08 Increased 2.319 
Stimulation of lymphocytes 1.18E-09 Increased 2.211 
Chemotaxis of granulocytes 5.04E-09 Increased 2.154 
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Table 7:             
              
Gene 
AL vs NAWM RM vs NAWM IdL vs NAWM 
Array qPCR Array qPCR Array qPCR 
              
MAL -1.42 -1.93 -1.59 -1.80 -3.50 -3.85 
MAG -1.46 -1.47 -1.18 -1.38 -3.37 -2.83 
IL4R 2.35 1.31 4.43 1.18 5.9 1.43 
STAT6 1.99 1.58 2.7 1.16 3.1 1.71 
CXCL12 1.88 1.92 2.25 2.02 2.76 3.56 
IGF2 1.54 1.22 -1.11 1.25 2.90 2.22 
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Highlights 
 Lesion tissues express both, oligodendrogliogenesis promoting and inhibiting 
genes 
 Gene expression patterns vary significantly in single lesion tissue types 
 Gene expression heterogeneity might be causative for non-uniform 
remyelination 
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